top of page
ABOUT TMS
Martin Jamieson, Chairman and CEO, Nexstim Plc commented: "We are extremely pleased to announce the launch of our NBT® system for depression at this TMS focused event. The unique navigational capability of our system, personalised to each patient for targeted stimulation of the relevant brain area, clearly differentiates it from the non-navigational TMS devices currently on the market for this indication."
TMS is FDA APPROVED for Treatment Resistant Major Depressive Disorder
TMS Depression Survey
Are you a candidate?
bottom of page